Cargando…

Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer

OBJECTIVES: Recent clinical studies have demonstrated that immunotherapy-based neoadjuvant therapy have promising effectiveness for patients with resectable non-small cell lung cancer (NSCLC) in terms of pathologic response. Therefore, we performed this study to investigate whether immunotherapy-bas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Jie, Gu, Linping, Qi, Yuwen, Yao, Yaxian, Lu, Shun, Chen, Zhiwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560710/ https://www.ncbi.nlm.nih.gov/pubmed/37818382 http://dx.doi.org/10.3389/fimmu.2023.1268251

Ejemplares similares

An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer
por: Qi, Yuwen, et al.
Publicado: (2023)

An open, observational, three-arm clinical study of 2–3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis
por: Gu, Linping, et al.
Publicado: (2022)

Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world
por: Fang, Min, et al.
Publicado: (2023)

Neoadjuvant immunotherapy for resectable esophageal cancer: A review
por: Li, Qing, et al.
Publicado: (2022)

Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis
por: Li, Shuling, et al.
Publicado: (2022)

Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer
por: Wu, Yijun, et al.
Publicado: (2022)

Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis
por: Xu, Jiawei, et al.
Publicado: (2022)

Tumor microenvironment features decipher the outperformance of neoadjuvant immunochemotherapy over chemotherapy in resectable non-small cell lung cancer
por: Cai, Wenhan, et al.
Publicado: (2022)

An inter-correlation among chemokine (C-X-C motif) ligand (CXCL) 1, CXCL2 and CXCL8, and their diversified potential as biomarkers for tumor features and survival profiles in non-small cell lung cancer patients
por: Gu, Linping, et al.
Publicado: (2021)

Neoadjuvant immunotherapy in resectable non-small-cell lung cancer
por: Chen, Lanyi Nora, et al.
Publicado: (2023)

Evaluation of neoadjuvant immunotherapy and traditional neoadjuvant therapy for resectable esophageal cancer: a systematic review and single-arm and network meta-analysis
por: Wang, Hesong, et al.
Publicado: (2023)

Erratum: Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer
Publicado: (2022)

The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
por: Jiang, Long, et al.
Publicado: (2021)

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
por: Wu, Xinyu, et al.
Publicado: (2023)

Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma
por: Li, Chao, et al.
Publicado: (2022)

Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges
por: Ren, Sijia, et al.
Publicado: (2020)

Neoadjuvant immunotherapy in resectable non-small cell lung cancer at a checkpoint
por: Faltermeier, Claire M., et al.
Publicado: (2021)

Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
por: Parekh, Jay, et al.
Publicado: (2023)

Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials
por: Zhu, Jie, et al.
Publicado: (2022)

Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review
por: Gatteschi, Lavinia, et al.
Publicado: (2021)

Meta-Analysis of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer
por: Cao, Christopher, et al.
Publicado: (2021)

Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
por: Huynh, Caroline, et al.
Publicado: (2021)

A real‐world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non‐small cell lung cancer
por: Zhang, Baihua, et al.
Publicado: (2022)

Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP)
por: Faehling, Martin, et al.
Publicado: (2022)

Real-World Effectiveness and Prognostic Factors Analysis of Stages I–III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy
por: Liu, Zuo, et al.
Publicado: (2021)

Evaluation of neoadjuvant immunotherapy plus chemotherapy in Chinese surgically resectable gastric cancer: a pilot study by meta-analysis
por: Xu, Hao, et al.
Publicado: (2023)

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
por: Yang, Chang, et al.
Publicado: (2020)

Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real−world retrospective study
por: Wu, Wen-Jie, et al.
Publicado: (2023)

The earlier, the better? A review of neoadjuvant immunotherapy in resectable non‐small‐cell lung cancer
por: Li, Fajiu, et al.
Publicado: (2022)

The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis
por: He, Wenwu, et al.
Publicado: (2023)

Neoadjuvant immunotherapy facilitates resection of surgically-challenging lung squamous cell cancer
por: Xu, Ke, et al.
Publicado: (2021)

Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?
por: Zhu, Jiahao, et al.
Publicado: (2023)

Neoadjuvant immunotherapy and neoadjuvant chemotherapy in resectable non-small cell lung cancer: A systematic review and single-arm meta-analysis
por: Wang, He, et al.
Publicado: (2022)

Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer
por: Zhou, Long, et al.
Publicado: (2023)

Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy
por: Shi, Yanhong, et al.
Publicado: (2023)

Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer
por: Liu, Chaoyuan, et al.
Publicado: (2023)

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era
por: Li, Huanhuan, et al.
Publicado: (2023)

Comprehensive (18)F-FDG PET-based radiomics in elevating the pathological response to neoadjuvant immunochemotherapy for resectable stage III non-small-cell lung cancer: A pilot study
por: Cui, Yingpu, et al.
Publicado: (2022)

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer
por: Chen, Hualin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ep867fm4mtestfqi65l8aqjk17